Heme-iron oxygenases: powerful industrial biocatalysts?

Current Opinion in Chemical Biology

Volumn 12, Issue 2, 2008, Pages 177-186

  Julsing, Mattijs K ^a   Cornelissen, Sjef ^a   Bühler, Bruno ^a   Schmid, Andreas ^a,b  

^a TU DORTMUND UNIVERSITY   (Germany)

^b LEIBNIZ INSTITUT FÜR ANALYTISCHE WISSENSCHAFTEN ISAS E V   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISINIC ACID; ARTEMISININ; BACTERIAL ENZYME; BACTERIAL PROTEIN; CARBON; COMPACTIN; CYTOCHROME P450; DICARBOXYLIC ACID; DRUG METABOLITE; HEME IRON OXYGENASE; HYDROCORTISONE; HYDROGEN; OXYGENASE; PRAVASTATIN; SIMVASTATIN; STEROID; TERPENOID DERIVATIVE; UNSPECIFIC MONOOXYGENASE; VEGETABLE PROTEIN;

BIOCATALYST; BIOTRANSFORMATION; CATALYSIS; CHEMICAL BOND; DRUG INDUSTRY; DRUG MANUFACTURE; ENGINEERING; ENZYME ACTIVITY; ENZYME ENGINEERING; ENZYME SPECIFICITY; ENZYME STABILITY; FERMENTATION; GENE EXPRESSION; HEME SYNTHESIS; METABOLIC ENGINEERING; NONHUMAN; OXIDATION; PROTEIN ENGINEERING; REVIEW; SITE DIRECTED MUTAGENESIS;

ANIMALS; BIOTECHNOLOGY; CATALYSIS; CHEMICAL INDUSTRY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PROTEIN ENGINEERING;

EID: 43049128108     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2008.01.029     Document Type: Review

References (68)

1. Bernhardt R. Cytochromes P450 as versatile biocatalysts. J Biotechnol 124 (2006) 128-145. This review nicely introduces the current knowledge on the molecular basis of CYP450 catalysis and gives some examples for CYP450 applications and protein engineering.
2. Urlacher V.B., and Eiben S. Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotechnol 24 (2006) 324-330
3. Gillam E.M.J. Extending the capabilities of nature's most versatile catalysts: directed evolution of mammalian xenobiotic-metabolizing P450s. Arch Biochem Biophys 464 (2007) 176-186. This review focuses specifically on the application of directed evolution strategies for mammalian CYP450 and sets the achievements of these technologies into context with the requirements for industrial process implementation.
4. Volokhan O., Sletta H., Ellingsen T.E., and Zotchev S.B. Characterization of the P450 monooxygenase NysL, responsible for C-10 hydroxylation during biosynthesis of the polyene macrolide antibiotic nystatin in Streptomyces noursei. Appl Environ Microbiol 72 (2006) 2514-2519
5. Teoh K.H., Polichuk D.R., Reed D.W., Nowak G., and Covello P.S. Artemisia annua L. (Asteraceae) trichome-specific cDNAs reveal CYP71AV1, a cytochrome P450 with a key role in the biosynthesis of the antimalarial sesquiterpene lactone artemisinin. FEBS Lett 580 (2006) 1411-1416
6. Jennewein S., Long R.M., Williams R.M., and Croteau R. Cytochrome p450 taxadiene 5α-hydroxylase, a mechanistically unusual monooxygenase catalyzing the first oxygenation step of taxol biosynthesis. Chem Biol 11 (2004) 379-387
7. Chau M., and Croteau R. Molecular cloning and characterization of a cytochrome P450 taxoid 2α-hydroxylase involved in Taxol biosynthesis. Arch Biochem Biophys 427 (2004) 48-57
8. Schmid A., Dordick J.S., Hauer B., Kiener A., Wubbolts M., and Witholt B. Industrial biocatalysis today and tomorrow. Nature 409 (2001) 258-268
9. Bistolas N., Wollenberger U., Jung C., and Scheller F.W. Cytochrome P450 biosensors - a review. Biosens Bioelectron 20 (2005) 2408-2423
10. Shumyantseva V.V., Bulko T.V., and Archakov A.I. Electrochemical reduction of cytochrome P450 as an approach to the construction of biosensors and bioreactors. J Inorg Biochem 99 (2005) 1051-1063
11. Ruinatscha R., Hollrigl V., Otto K., and Schmid A. Productivity of selective electroenzymatic reduction and oxidation reactions: theoretical and practical considerations. Adv Synth Catal 348 (2006) 2015-2026
12. Straathof A.J., Panke S., and Schmid A. The production of fine chemicals by biotransformations. Curr Opin Biotechnol 13 (2002) 548-556. This review discusses the status of biocatalysis in industry in 2002 and provides detailed information on many examples of industrially applied biotransformations. Based on these data, typical product concentrations and productivities of successful processes are given.
13. Pollard D.J., and Woodley J.M. Biocatalysis for pharmaceutical intermediates: the future is now. Trends Biotechnol 25 (2007) 66-73
14. Woodley J.M., and Titchener-Hooker N.J. The use of windows of operation as a bioprocess design tool. Bioprocess Eng 14 (1996) 263-268
15. Noble M.A., Miles C.S., Chapman S.K., Lysek D.A., Mackay A.C., Reid G.A., Hanzlik R.P., and Munro A.W. Roles of key active-site residues in flavocytochrome P450 BM3. Biochem J 339 (1999) 371-379
16. Duetz W.A., van Beilen J.B., and Witholt B. Using proteins in their natural environment: potential and limitations of microbial whole-cell hydroxylations in applied biocatalysis. Curr Opin Biotechnol 12 (2001) 419-425
17. -1, thereby reaching the highest expression level reported for CYP450s.
18. Gbewonyo K., Buckland B.C., and Lilly M.D. Development of a large-scale continuous substrate feed process for the biotransformation of simvastatin by Nocardia sp. Biotechnol Bioeng 37 (1991) 1101-1107
19. -1. Consider also Ref. [36] for this process.
20. van Beilen J.B., Holtackers R., Luscher D., Bauer U., Witholt B., and Duetz W.A. Biocatalytic production of perillyl alcohol from limonene by using a novel Mycobacterium sp. cytochrome P450 alkane hydroxylase expressed in Pseudomonas putida. Appl Environ Microbiol 71 (2005) 1737-1744. In one of the most integrated and productive approaches reported for CYP450-biocatalysis, van Beilen et al. applied a two-liquid phase system for in situ product removal and improved substrate availability. This allowed the conversion of poorly water-soluble (-)-limonene to toxic (-)-perillyl alcohol.
21. Maurer S.C., Kuhnel K., Kaysser L.A., Eiben S., Schmid R.D., and Urlacher V.B. Catalytic hydroxylation in biphasic systems using CYP102A1 mutants. Adv Synth Catal 347 (2005) 1090-1098
22. Park J.W., Lee J.K., Kwon T.J., Yi D.H., Kim Y.J., Moon S.H., Suh H.H., Kang S.M., and Park Y.I. Bioconversion of compactin into pravastatin by Streptomyces sp. Biotechnol Lett 25 (2003) 1827-1831
23. Schneider S., Wubbolts M.G., Oesterhelt G., Sanglard D., and Witholt B. Controlled regioselectivity of fatty acid oxidation by whole cells producing cytochrome P450 BM3 monooxygenase under varied dissolved oxygen concentrations. Biotechnol Bioeng 64 (1999) 333-341
24. Peters F.T., Dragan C.A., Wilde D.R., Meyer M.R., Zapp J., Bureik M., and Maurer H.H. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4′-hydroxymethyl-α-pyrrolidinobutyrophenone. Biochem Pharmacol 74 (2007) 511-520. The oxidation of 4′-hydroxmethyl-α-pyrrolidinobutyrophenone by Schizosaccharomyces pombe overexpressing CYP2D6 on a 1 l scale shows the feasibility of using human CYP450 enzymes for the synthesis of drug metabolites. The hydroxylated product was isolated to 98% purity.
25. Duport C., Spagnoli R., Degryse E., and Pompon D. Self-sufficient biosynthesis of pregnenolone and progesterone in engineered yeast. Nat Biotechnol 16 (1998) 186-189
26. Takeda K., Asou T., Matsuda A., Kimura K., Okamura K., Okamoto R., Sasaki J., Adachi T., and Omura S. Application of cyclodextrin to microbial transformation of vitamin D3 to 25-hydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3. J Ferm Bioeng 78 (1994) 380-382
27. Liu Y., Kondo A., Ohkawa H., Shiota N., and Fukuda H. Bioconversion using immobilized recombinant flocculent yeast cells carrying a fused enzyme gene in an 'intelligent' bioreactor. Biochem Eng J 2 (1998) 229-235
28. Sasaki J., Miyazaki A., Saito M., Adachi T., Mizoue K., Hanada K., and Omura S. Transformation of vitamin D3 to 1α,25-dihydroxyvitamin D3 via 25-hydroxyvitamin D3 using Amycolata sp. strains. Appl Microbiol Biotechnol 38 (1992) 152-157
29. Ro D.K., Paradise E.M., Ouellet M., Fisher K.J., Newman K.L., Ndungu J.M., Ho K.A., Eachus R.A., Ham T.S., Kirby J., et al. Production of the antimalarial drug precursor artemisinic acid in engineered yeast. Nature 440 (2006) 940-943. To enable the production of the antimalarial drug artemisinin from cheap and renewable substrates, S. cerevisiae has been engineered to produce artemisinic acid from simple sugars. The constructed artificial biosynthetic pathway consisted of an engineered endogenous terpenoid pathway, amorphadiene synthase, and CYP71AV1, which catalyses a three-step hydroxylation.
30. Lilly M.D., and Woodley J.M. A structured approach to design and operation of biotransformation processes. J Ind Microbiol 17 (1996) 24-29
31. Shibasaki T., Mori H., and Ozaki A. Enzymatic production of trans-4-hydroxy-l-proline by regio- and stereospecific hydroxylation of l-proline. Biosci Biotech Biochem 64 (2000) 746-750
32. Park J.B., Bühler B., Habicher T., Hauer B., Panke S., Witholt B., and Schmid A. The efficiency of recombinant Escherichia coli as biocatalyst for stereospecific epoxidation. Biotechnol Bioeng 95 (2006) 501-512
33. Kiener A. Biosynthesis of functionalized aromatic N-heterocycles. Chemtech 25 (1995) 2-12
34. Bühler B., Bollhalder I., Hauer B., Witholt B., and Schmid A. Use of the two-liquid phase concept to exploit kinetically controlled multistep biocatalysis. Biotechnol Bioeng 81 (2003) 683-694
35. Cao Z., Gao H., Liu M., and Jiao P. Engineering the acetyl-CoA transportation system of Candida tropicalis enhances the production of dicarboxylic acid. Biotechnol J 1 (2006) 68-74
36. Picataggio S., Rohrer T., Deanda K., Lanning D., Reynolds R., Mielenz J., and Eirich L.D. Metabolic engineering of Candida tropicalis for the production of long chain dicarboxylic acids. Biotechnology (NY) 10 (1992) 894-898
37. Cojocaru V., Winn P.J., and Wade R.C. The ins and outs of cytochrome P450s. Biochim Biophys Acta 1770 (2007) 390-401
38. Schleinkofer K., Sudarko, Winn P.J., Ludemann S.K., and Wade R.C. Do mammalian cytochrome P450s show multiple ligand access pathways and ligand channelling?. EMBO Rep 6 (2005) 584-589
39. Cirino P.C., and Arnold F.H. Protein engineering of oxygenases for biocatalysis. Curr Opin Chem Biol 6 (2002) 130-135
40. Yun C.H., Yim S.K., Kim D.H., and Ahn T. Functional expression of human cytochrome P450 enzymes in Escherichia coli. Curr Drug Metab 7 (2006) 411-429. Very detailed review on all aspects involved in the heterologous expression of human CYP450 enzymes.
41. Pechurskaya T.A., Harnastai I.N., Grabovec I.P., Gilep A.A., and Usanov S.A. Adrenodoxin supports reactions catalyzed by microsomal steroidogenic cytochrome P450s. Biochem Biophys Res Commun 353 (2007) 598-604. This study shows that CYP17A1 can accept electrons form different redox partners and that N-terminal sequence modification can be beneficial or detrimental depending on the presence of redox partners.
42. Kim D.H., Kim K.H., Isin E.M., Guengerich F.P., Chae H.Z., Ahn T., and Yun C.H. Heterologous expression and characterization of wild-type human cytochrome P450 1A2 without conventional N-terminal modification in Escherichia coli. Protein Expr Purif 57 (2008) 188-200
43. Pritchard M.P., Ossetian R., Li D.N., Henderson C.J., Burchell B., Wolf C.R., and Friedberg T. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6, and CYP2E1. Arch Biochem Biophys 345 (1997) 342-354
44. Wu Z.L., Sohl C.D., Shimada T., and Guengerich F.P. Recombinant enzymes overexpressed in bacteria show broad catalytic specificity of human cytochrome P450 2W1 and limited activity of human cytochrome P450 2S1. Mol Pharmacol 69 (2006) 2007-2014
45. -1 artemisinic acid, a synthon for the antimalarial drug artemisinin, from simple sugars. The efficient formation of unfunctionalized terpenoid building blocks and subsequent tailoring by CYP450 catalysis represents a promising platform technology for terpenoid synthesis.
46. Xu F., Bell S.G., Lednik J., Insley A., Rao Z., and Wong L.L. The heme monooxygenase cytochrome P450cam can be engineered to oxidize ethane to ethanol. Angew Chem Int Ed Engl 44 (2005) 4029-4032. This is one of the first studies reporting the oxidation of alkanes as small as ethane by a CYP450 enzyme. This was achieved by site-directed mutagenesis of CYP101A1.
47. Fasan R., Chen M.M., Crook N.C., and Arnold F.H. Engineered alkane-hydroxylating cytochrome P450(BM3) exhibiting nativelike catalytic properties. Angew Chem Int Ed Engl 46 (2007) 8414-8418. This study describes directed evolution of CYP102A1 to improve catalytic activity of the enzyme towards the unnatural substrate propane. It clearly shows the relation between coupling efficiency, activity, and stability of the enzyme.
48. Li Y., Drummond D.A., Sawayama A.M., Snow C.D., Bloom J.D., and Arnold F.H. A diverse family of thermostable cytochrome P450s created by recombination of stabilizing fragments. Nat Biotechnol 25 (2007) 1051-1056. Recombination of stabilizing fragments combined with impressive high-throughput screening approach allowed to significantly increase the thermostability of CYP102A1.
49. Joo H., Lin Z., and Arnold F.H. Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation. Nature 399 (1999) 670-673
50. Cirino P.C., and Arnold F.H. A self-sufficient peroxide-driven hydroxylation biocatalyst. Angew Chem Int Ed Engl 42 (2003) 3299-3301
51. Schwaneberg U., Schmidt-Dannert C., Schmitt J., and Schmid R.D. A continuous spectrophotometric assay for P450 BM-3, a fatty acid hydroxylating enzyme, and its mutant F87A. Anal Biochem 269 (1999) 359-366
52. Chefson A., Zhao J., and Auclair K. Replacement of natural cofactors by selected hydrogen peroxide donors or organic peroxides results in improved activity for CYP3A4 and CYP2D6. Chembiochem 7 (2006) 916-919
53. Kumar S., Liu H., and Halpert J.R. Engineering of cytochrome P450 3A4 for enhanced peroxide-mediated substrate oxidation using directed evolution and site-directed mutagenesis. Drug Metab Dispos 34 (2006) 1958-1965
54. Hanlon S.P., Friedberg T., Wolf C.R., Ghisalba O., and Kittelmann M. Recombinant yeast and bacteria that express human P450s: bioreactors for drug discovery, development, and biotechnology. In: Schmid R.D., and Urlacher V.B. (Eds). Modern Biooxidation - Enzymes, Reactions, and Applications (2007), Wiley-VCH 233-252
55. Kolar N.W., Swart A.C., Mason J.I., and Swart P. Functional expression and characterisation of human cytochrome P45017α in Pichia pastoris. J Biotechnol 129 (2007) 635-644
56. Ruijssenaars H.J., Sperling E.M., Wiegerinck P.H., Brands F.T., Wery J., and de Bont J.A. Testosterone 15β-hydroxylation by solvent tolerant Pseudomonas putida S12. J Biotechnol 131 (2007) 205-208
57. Harnastai I.N., Gilep A.A., and Usanov S.A. The development of an efficient system for heterologous expression of cytochrome P450s in Escherichia coli using hemA gene co-expression. Protein Expr Purif 46 (2006) 47-55
58. Uchida E., Kagawa N., Sakaki T., Urushino N., Sawada N., Kamakura M., Ohta M., Kato S., and Inouye K. Purification and characterization of mouse CYP27B1 overproduced by an Escherichia coli system coexpressing molecular chaperonins GroEL/ES. Biochem Biophys Res Commun 323 (2004) 505-511
59. Kagawa N., and Cao Q. Osmotic stress induced by carbohydrates enhances expression of foreign proteins in Escherichia coli. Arch Biochem Biophys 393 (2001) 290-296
60. Mouri T., Michizoe J., Ichinose H., Kamiya N., and Goto M. A recombinant Escherichia coli whole cell biocatalyst harboring a cytochrome P450cam monooxygenase system coupled with enzymatic cofactor regeneration. Appl Microbiol Biotechnol 72 (2006) 514-520
61. Lu Y., and Mei L.H. Co-expression of P450BM3 and glucose dehydrogenase by recombinant Escherichia coli and its application in an NADPH-dependent indigo production system. J Ind Microbiol Biotechnol 34 (2007) 247-253
62. Szczebara F.M., Chandelier C., Villeret C., Masurel A., Bourot S., Duport C., Blanchard S., Groisillier A., Testet E., Costaglioli P., et al. Total biosynthesis of hydrocortisone from a simple carbon source in yeast. Nat Biotechnol 21 (2003) 143-149. For the production of hydrocortisone from ethanol and glucose, an artificial pathway involving 13 engineered genes including 4 mammalian cytochrome P450s has been established in S. cerevisiae. Furthermore, endogenous sterol synthesis was rerouted.
63. Dumas B., Brocard-Masson C., Assemat-Lebrun K., and Achstetter T. Hydrocortisone made in yeast: metabolic engineering turns a unicellular microorganism into a drug-synthesizing factory. Biotechnol J 1 (2006) 299-307
64. Jose J., Bernhardt R., and Hannemann F. Cellular surface display of dimeric Adx and whole cell P450 mediated steroid synthesis on E. coli. J Biotechnol 95 (2002) 257-268
65. Ni Y., and Chen R.R. Lipoprotein mutation accelerates substrate permeability-limited toluene dioxygenase-catalyzed reaction. Biotechnol Prog 21 (2005) 799-805
66. Vail R.B., Homann M.J., Hanna I., and Zaks A. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J Ind Microbiol Biotechnol 32 (2005) 67-74
67. Bureik M., and Bernhardt R. Steroid hydroxylation: microbial steroid biotransformations using cytochrome P450 enzymes. In: Schmid R.D., and Urlacher V.B. (Eds). Modern Biooxidation - Enzymes, Reactions, and Applications (2007), Wiley-VCH 155-176
68. Allen J., Brasseur D.M., De Bruin B., Denoux M., Perard S., Philippe N., and Roy S.N. The use of biocatalysis in the synthesis of labelled compounds. J Labelled Comp Radiopharm 50 (2007) 342-346